Sphingosine Kinase Activity Is Not Required for Tumor Cell Viability

• Karen Rex ,

  Contributed equally to this work with: Karen Rex, Shawn Jeffries

  Affiliation Oncology Research, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Shawn Jeffries ,

  Contributed equally to this work with: Karen Rex, Shawn Jeffries

  Affiliation Oncology Research, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Matthew L. Brown,

  Affiliation Medicinal Chemistry, Amgen Inc., South San Francisco, California, United States of America

  ⨯
• Timothy Carlson,

  Affiliation Pharmacokinetics & Drug Metabolism, Amgen Inc., South San Francisco, California, United States of America

  ⨯
• Angela Coxon,

  Affiliation Oncology Research, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Flordeliza Fajardo,

  Affiliation Oncology Research, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Brendon Frank,

  Affiliation Oncology Research, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Darin Gustin,

  Affiliation Medicinal Chemistry, Amgen Inc., South San Francisco, California, United States of America

  ⨯
• Alexander Kamb,

  Affiliation Discovery Sciences, Amgen Inc., South San Francisco, California, United States of America

  ⨯
• Paul D. Kassner,

  Affiliation Genome Analysis Unit, Amgen Inc., South San Francisco, California, United States of America

  ⨯
• Shyun Li,

  Affiliation Oncology Research, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Yihong Li,

  Affiliation Medicinal Chemistry, Amgen Inc., South San Francisco, California, United States of America

  ⨯
• Kurt Morgenstern,

  Affiliation Molecular Structure and Characterization, Amgen Inc., Cambridge, Massachusetts, United States of America

  ⨯
• Matthew Plant,

  Affiliation Molecular Structure and Characterization, Amgen Inc., Cambridge, Massachusetts, United States of America

  ⨯
• Kim Quon,

  Affiliation Therapeutic Innovation Unit, Amgen Inc., Seattle, Washington, United States of America

  ⨯
• Astrid Ruefli-Brasse,

  Affiliation Oncology Research, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Joanna Schmidt,

  Affiliation Oncology Research, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Elissa Swearingen,

  Affiliation Genome Analysis Unit, Amgen Inc., South San Francisco, California, United States of America

  ⨯
• Nigel Walker,

  Affiliation Molecular Structure and Characterization, Amgen Inc., Cambridge, Massachusetts, United States of America

  ⨯
• Zhulun Wang,

  Affiliation Molecular Structure and Characterization, Amgen Inc., Cambridge, Massachusetts, United States of America

  ⨯
• J. E. Vivienne Watson,

  Affiliation Oncology Research, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Dineli Wickramasinghe,

  Affiliation Oncology Research, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Mariwil Wong,

  Affiliation Oncology Research, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• Guifen Xu,

  Affiliation Pharmacokinetics & Drug Metabolism, Amgen Inc., South San Francisco, California, United States of America

  ⨯
•  [ ... ],
• Holger Wesche

  * E-mail: hwesche@amgen.com

  Affiliation Oncology Research, Amgen Inc., Thousand Oaks, California, United States of America

  ⨯
• [ view all ]
• [ view less ]